Patrick Vanscheeuwijck
      OUR PEOPLE

      Dr. Patrick Vanscheeuwijck

      Post-doctorate in Molecular Biology and Molecular Pharmacology, PhD in Biochemical Pharmacology, MSc in Biochemistry

      Vice President Science for Product Innovation

      Contact

      Patrick is Vice President Science for Product Innovation in Life Sciences. He joined PMI in 1995 as a Bioresearch Manager in a PMI research laboratory. He holds a Post-doctorate in Molecular Biology from KU Leuven, a Post-doctorate in Molecular Pharmacology from the University of Arizona, a PhD in Biochemical Pharmacology and a master’s in Science, Biochemistry, from Ghent University.

      At PMI, Patrick has held various positions, including as General Manager of two PMI research laboratories, specializing in experimental biology and toxicology, chemistry, in vitro and in vivo toxicology, and Director, Pre-clinical Toxicology. He spent the first part of his career at PMI developing and applying preclinical science to support the early development of the smoke-free products category. He has published numerous articles in international scientific journals. In 2021 Patrick took up the role of Vice President Smoke-Free Products Category to accelerate smoke-free products market growth by integrating and leading the Life Science components of PMI's smoke-free products business strategy.

      Latest Publications

      PMIScience.com is operated by Philip Morris International for the purpose of publishing and disseminating scientific information about Philip Morris International’s efforts in support of its smoke-free product portfolio. This site is a global site for use by scientists, the public health and regulatory communities, and other stakeholders with an interest in tobacco policy. The purpose of this site is not advertising or marketing, nor is it directed at any specific market. It is not intended for use by consumers. New tobacco products sold in the United States are subject to FDA regulation; therefore the content of this site is not intended to make, and nor should it be construed as making, any product related claims in the United States without proper FDA authorization. ​
      ​
      Reduced Risk Products ("RRPs”) is the term we use to refer to products that present, are likely to present, or have the potential to present less risk of harm to smokers who switch to these products versus continuing smoking. PMI has a range of RRPs in various stages of development, scientific assessment and commercialization. All of our RRPs are smoke-free products that deliver nicotine with far lower quantities of harmful and potentially harmful constituents than found in cigarette smoke.